AQST-109 is under clinical development by Aquestive Therapeutics and currently in Phase I for Anaphylaxis. According to GlobalData, Phase I drugs for Anaphylaxis have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AQST-109’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AQST-109 overview

Epinephrine (AQST-109) is under development for the treatment of allergic reactions including anaphylaxis. It is administered through sublingual route as film. The drug candidate is being developed based on PharmFilm technology.

Aquestive Therapeutics overview

Aquestive Therapeutics (Aquestive), is a Pharmaceutical company. It offers drug products. The company offers products that includes sympazan, a film formulation of clobazamor for treating seizures associated with Lennox-Gastaut syndrome (LGS); suboxone for the treatment of opioid dependence; zuplenz for the treatment of nausea and vomiting; and diazepam. It also provides nutraceuticals, packaging solutions, and consumer products. Aquestive provides PharmFilm, a drug delivery platform that delivers existing prescription products directly to the bloodstream. The company collaborates with other pharmaceutical companies for the development and commercialization of its pharmaceutical products. The company has manufacturing facility in Indiana, the US. Aquestive Therapeutics is headquartered in Warren, New Jersey, the US

For a complete picture of AQST-109’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.